Preclinical data presented at AACR virtual special conference showed NBTXR3 combo over­comes anti-PD-1 resistance, pro­motes strong abscopal effect and long-term anti-cancer memory

Combo therapy including augmented anti-tumor response in both irradiated and unirradiated (abscopal) tumors, improving local and distant tumor control, and increasing survival rate Survivor mice were immune to re-injections of tumor cells, maintained significantly higher percentages of memory immune cells and stronger anti-tumor immune activities than control “Evaluation of NBTXR3 as a tumor-agnostic, combo-agnostic product candidate is instrumental to our aim of significantly improving treatment outcomes for millions of patients with cancer. Our early clinical data in several tumor types have support that the physical primary mode of action of NBTXR3 could be universal and potentially benefit patients with any tumor type where radiotherapy is part of the standard of care. Our prior pre-clinical and early data from our ongoing clinical I/O program have provided further support that the biological secondary immune priming effect of NBTXR3 could help patients overcome resistance to anti-PD-1. The data from this preclinical experiment suggest that we may be able to expand the application of NBTXR3 across checkpoint inhibitors, and long-term anti-tumor memory is an outcome we are eager to continue exploring.”  – Laurent Levy, CEO of Nanobiotix Paris, France ; Cambridge, Massachusetts (USA) ; March 2, 2021  –  NANOBIOTIX  (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced positive new preclinical data investigating first-in-class radioenhancer NBTXR3, which is being evaluated as a tumor-agnostic, combo-agnostic product candidate across several tumor types. The data is being shared via poster presentation at the first American Association of Cancer Research (AACR) Virtual Special Conference on Radiation Science and Medicine, held March 2-3, 2021, by researchers from the University of Texas MD Anderson Cancer Center (MD Anderson). Preclinical Data on NBTXR3 Combo NBTXR3 is composed of sterile, functionalized, crystalline hafnium oxide nanoparticles that are delivered by intratumoral injection one time prior to radiotherapy (XRT). After activation by XRT, the product candidate has a physical primary mechanism of action through which a higher dose of radiation is delivered within the tumor, enhancing the tumor-killing effect of XRT without increasing the dose in surrounding healthy tissues. The subsequent biological secondary mechanism of action that we are evaluating is the potential activation of several immune pathways upon tumor cell destruction, generating adaptive immune response within the body. NBTXR3 is being evaluated in an expansive global development plan both as a single agent activated by XRT and in combination with other anti-cancer therapies including chemotherapy and immune checkpoint inhibitors. This study examined NBTXR3 activated by XRT in combination with anti-PD-1 along with TIGIT and LAG3 inhibitors in an  in vivo  anti-PD-1 resistant mouse model (344SQR). Key Findings Include: The combination therapy of NBTXR3 + XRT + anti-PD-1 + anti-LAG3 + anti-TIGIT (Combo therapy) significantly promoted the proliferation activity of CD8 +  T cells, improved local and distant tumor control, and increased survival rate The anti-tumor efficacy of the Combo therapy was heavily dependent on CD4 +  and CD8 +  T cells The survivor mice from the groups treated with the Combo therapy were immune to re-injections of tumor cells The survivor mice maintained significantly higher percentages of memory CD4 +  and CD8 +  T cells, as well as stronger anti-tumor immune activities than control The Combo therapy augmented anti-tumor response in both irradiated and unirradiated (abscopal) tumors Poster Presentation Title:  Integration of anti-TIGIT and anti-LAG3 with NBTXR3-mediated Immunoradiation Therapy Improved Abscopal Effect and Induces Long-term Memory Against Cancer Timing:  View on-demand starting at 9:30am EST on March 2, 2021 on Virtual Conference platform Poster Number:  PO-040 About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Germany and Switzerland. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate– NBTXR3 —which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®. For more information about Nanobiotix, visit us at  www.nanobiotix.com  or follow us on  LinkedIn  and  Twitter . View source version on  businesswire.com :  https://www.businesswire.com/news/home/20220104005866/en/ Nanobiotix Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 [email protected] Investor Relations Department Kate McNeil SVP, Investor Relations +1 (609) 678-7388 [email protected] Media Relations France –  Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 [email protected] US –  Porter Novelli Dan Childs +1 (781) 888-5106 [email protected] Source: Nanobiotix

The release as fetched from its publisher. nanobiotix.com ↗